Anti-angiogenic therapy in renal cell carcinoma

Recent Patents on Anti-Cancer Drug Discovery

Volumn 5, Issue 1, 2010, Pages 77-83

  Sharma, Shree G ^a   Nanda, Sudip ^b   Longo, Santo ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ST LUKE S HOSPITAL   (United States)

Author keywords

Angiogenesis; Angiopoietins; Bevacizumab; Integrins; mTOR; Patents; Renal cell carcinoma; Sorafenib; Sumitinib; Temsirolimus; VEGF; VHL

Indexed keywords

AE 941; AFLIBERCEPT; ALPHA INTERFERON; AMG 386; ANGIOGENESIS INHIBITOR; AXITINIB; BATIMASTAT; BEVACIZUMAB; CILENGITIDE; ENZASTAURIN; EVEROLIMUS; HUMV 833; IMC 18F1; IMCL 1121 B; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MARIMASTAT; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY LM 609; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; NANOPARTICLE; PLACEBO; RECEPTOR ANTIBODY; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; VOLOCIXIMAB; INTEGRIN; MONOCLONAL ANTIBODY; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; VASCULOTROPIN A; VON HIPPEL LINDAU PROTEIN;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; ASTHENIA; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY CARCINOMA; METASTASIS; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN MANIFESTATION; STOMATITIS; TREATMENT OUTCOME; TUMOR VASCULARIZATION; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENETICS; KIDNEY TUMOR; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATENT; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; INTEGRINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; PATENTS AS TOPIC; PROTEIN-SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77649240428     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489210789702181     Document Type: Article

References (50)

1. Cancer facts and figures. American Cancer Society Inc.,Surveillance Research. 4.
2. National Comprehensive Cancer Network. Practice guidelines inoncology. pg KID-2 V.1.2009.
3. Fox SB. Tumour angiogenesis and prognosis. Histopathology 1997;30(3): 294-301.
4. Patan S, Munn LL, Jain RK. Intussusceptive microvascular growthin a human colon adenocarcinoma xenograft: A novel mechanismof tumor angiogenesis. Microvasc Res 1996; 51(2): 260-272.
5. Nikitenko L, Boshoff C. Endothelial cells and cancer. The vascularendothelium II. Handbook of experimental pharmacology. Springer-Verlag Berlin: Heidelberg 2006; 176: 318.
6. Ruoslahti E. Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans 2004; 32(Pt3): 397-402.
7. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: Noveltargeted therapies for renal cell cancer. Pharmacotherapy 2007;27(8): 1125-1144.
8. th ed.Freeman WH Company: New York 2004; 620-621.
9. Grothey A, Ellis LM. Targeting angiogenesis driven by vascularendothelial growth factors using antibody-based therapies. Cancer J 2008; 14(3): 170-177.
10. Veeravagu A, Hsu AR, Cai W, et al. Vascular endothelial growthfactor and vascular endothelial growth factor receptor inhibitors asanti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov 2007; 2(1): 59-71.
11. th Ed. Molecular cell biology. Freeman WHCompany: New York 2004; 587-598.
12. Gunningham SP, Currie MJ, Han C, et al. Vascular endothelialgrowth factor-B and vascular endothelial growth factor-Cexpression in renal cell carcinomas: Regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 2001; 1; 61(7): 3206-3211.
13. Ahmad SA, Liu W, Jung YD, et al. The effects of angiopoietin-1and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001; 61(4): 1255-1259.
14. Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO. Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 2001; 276(28): 26516-26525.
15. Ruoslahti E, Rajotte D. An address system in the vasculature ofnormal tissues and tumors. Annu Rev Immunol 2000; 18: 813-827.
16. Folgueras AR, Pendás AM, Sánchez LM, López-Otín C. Matrixmetalloproteinases in cancer: From new functions to improvedinhibition strategies. Int J Dev Biol 2004; 48(5-6): 411-424.
17. Pantuck AJ, Thomas G, Belldegrun AS, Figlin RA. Mammaliantarget of rapamycin inhibitors in renal cell carcinoma: Currentstatus and future applications. Semin Oncol 2006; 33(5): 607-613.
18. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase IIstudy of multiple dose levels of CCI-779, a novel mammalian targetof rapamycin kinase inhibitor, in patients with advanced refractoryrenal cell carcinoma. J Clin Oncol 2004; 22(5): 909-918.
19. Choueiri TK, Bukowski RM, Rini BI. The current role ofangiogenesis inhibitors in the treatment of renal cell carcinoma. Semin Oncol 2006; 33(5): 596-606.
20. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferonalfa compared with interferon alfa monotherapy in patients withmetastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33): 5422-5428.
21. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plusinterferon alfa-2a for treatment of metastatic renal cell carcinoma:A randomised, double-blind phase III trial. Lancet 2007; 370(9605):2103-2111.
22. Escudier B, Eisen T, Stadler WM, et al. TARGET Study Group.Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134.
23. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: Noveltargeted therapies for renal cell cancer. Pharmacotherapy 2007;27(8): 1125-1144.
24. Rini BI, Small EJ. Biology and clinical development of vascularendothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23(5): 1028-1043.
25. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus inadvanced renal cell carcinoma: A double-blind, randomised,placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-456.
26. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatmentin patients with cytokine-refractory metastatic renal-cell cancer: Aphase II study. Lancet Oncol 2007; 8(11): 975-984.
27. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferonalfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-2281.
28. Strimpakos AS, Karapanagiotou EM, Saif WM, Syrigos KN. Therole of mTOR in the management of solid tumors: An overview. Cancer Treat Rev 2008. doi:10.1016/j.ctrv.2008.09.006.
29. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus inadvanced renal cell carcinoma: A double-blind randomised,placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-456.
30. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging andbiological evaluation of HuMV833 anti-VEGF antibody:implications for trial design of antiangiogenic antibodies. J NatlCancer Inst 2002; 94(19): 1484-1493.
31. Keyes KA, Mann L, Sherman M, et al. LY317615 decreases plasmaVEGF levels in human tumor xenograft-bearing mice. CancerChemother Pharmacol 2004; 53(2): 133-140.
32. Sawhney R, Kabbinavar F. Angiogenesis and angiogenic inhibitorsin renal cell carcinoma. Curr Urol Rep 2008; 9(1): 26-33.
33. Kuwada SK. Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr Opin Mol Ther 2007; 9(1): 92-98.
34. Chan LS, Daruwalla J, Christophi C. Selective targeting of thetumour vasculature. ANZ J Surg 2008; 78(11): 955-967.
35. Murphy EA, Majeti BK, Barnes LA, et al. Nanoparticle-mediateddrug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008; 105(27): 9343-9348.
36. Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumorangiogenesis in vivo by alphaVbeta3-targeted magnetic resonanceimaging. Nat Med 1998; 4(5): 623-626.
37. Dupont, E., Brazeau, P., Juneau, C.: US5618925 (1997)
38. Batist G, Patenaude F, Champagne P, et al. Neovastat (AE-941) inrefractory renal cell carcinoma patients: report of a phase II trialwith two dose levels. Ann Oncol 2002; 13(8): 1259-63.
39. Muraishi Y, Mitani N, Fuse H, Saiki I. Effect of a matrixmetalloproteinase inhibitor (ONO-4817) on lung metastasis ofmurine renal cell carcinoma. Anticancer Res 2001; 21(6A): 3845-3852.
40. Baca, M., Wells, J. A., Presta, L. G., Lowman, H. B., Chen, Y. M.Y.: US7375193 (2008).
41. Holash, J., Jaffe, R., Hu, L., Yancopoulos, G. D.: US7354579 (2008).
42. Thompson, J.W., Fetter, R.J., Bellet, R.E., Li H.: US6538029 (2003).
43. Creaven, J.P.: US4994440 (1991).
44. Hirsch, F., Angevin E.: US7074613 (2006).
45. Luxon, A.B., Copland, A.J., Wood, G. C.: US20050130193A1 (2005).
46. Nakamura, Y., Katagiri, T.: US20070059814A1 (2007).
47. Heavner, A.G., Giles-Kornor, M.J., Knight, M.D., Scallon, J.B., Shealy, J.D.: US20070160606A1 (2007).
48. Folkman J, Browder T, Palmblad J. Angiogenesis research:guidelines for translation to clinical application. Thromb Haemost 2001; 86(1): 23-33.
49. Ruoslahti E. Drug targeting to specific vascular sites. Drug DiscovToday 2002; 7(22): 1138-1143.
50. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9(6): 685-693.